Legal issues restrictions

Perhaps the polymer exemption approach in the US under the TSCA comes closest to striking a balance between the overly lenient approach in the EU and the overly conservative approach in Canada. The molecular weight requirements and restrictions on reactive functionalities and certain physical attributes defined under the exemption go a long way toward defining a better way of regulating polymers. This approach could resolve the legal issue under REACH involving the requirement that monomers in reacted form in polymers... 

Legal issues together with scientific and technical complications restrict legal intervention. 

Risk managers are confronted with a host of fairly complex technical, legal, and social issues when making decisions about whether to restrict people s exposure to consumer products, drugs, food ingredients, and environmental chemicals, and about the degree of restriction that is necessary. When all of this complex analysis is done, however, the manager needs to be able to face the public and declare that the final decision will ensure that their health will be protected. The... 

Other chapters in this book deal with the evolution of the legal controls over medicinal products and the structure of the European Union regulatory systems set up to authorise business activities and dealings in these products, and to enforce the rules and restrictions the law places upon them. This chapter aims to select some specific legal and ethical issues that arise in relation to product development, authorisation and sale and supply both within the United Kingdom and within the context of the European systems. 

December Smith Wesson enters into a legal setdement with the city of Boston. It resolves some of the issues in the earlier failed agreement, and is restricted only to Smith Wesson s products. However, a number of gun advocacy groups organize a boycott of Smith Wesson to protest what they view as caving in to antigun forces. 

The issue of off-label information is certain to remain controversial for some time, with the FDA seeking ways to restrict the dissemination of off-label information about prescription drugs and the legal community and industry seeking ways to provide such information to health professionals without stimulating enforcement actions. 

The pricing and reimbursement of medicines cire still special issues in Hungary. Until 1997, legal (prescription) and reimbursement status were not fully separated and both were specified by the Ministry of Health. Application of a more restricted prescription status for expensive medicines was not uncommon. Since 1997, the legal status is specified, applying professional criteria exclusively, by the regulatory authority when the MA is issued. 

The legal basis for an IND was set up in the 1962 amendments. It is unlawful to transport an unapproved drug across state lines unless FDA has issued an exemption. The IND is technically an exemption from the requirements of an NDA. Dmgs labeled Not for human use are also exempt from the NDA requirements, before being transported, but carry regulatory restrictions. Note that technically and legally these regulations apply just as much to noncommercial research physicians, for example in universities, as to pharmaceutical companies. 

Trade Data. Most of these agencies can provide statistics on imports and exports, production, tariffs, and other legal regulations for their countries. Many offices issue periodic statistical bulletins—for instance, the Ceylon Trade Journal hQ Economic Survey (of Helsinki), and the Addis Ababa Monthly Report on Economic Conditions. A separate list of the seriallike publications mentioned in the source list, but not restricted to the trade field, appears in Table II. 

---